12:00 AM
Apr 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VNP20009: Began Phase I testing

Vion Pharmaceuticals Inc. (VION), New Haven, Conn.
Product: VNP20009
Business: Cancer
Therapeutic category: Cytotoxic
Target: Tumor cells
Description: First generation TAPET (tumor...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >